CYP Stock Overview
Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cynata Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.21 |
| 52 Week High | AU$0.34 |
| 52 Week Low | AU$0.10 |
| Beta | 0.91 |
| 11 Month Change | -10.42% |
| 3 Month Change | 2.38% |
| 1 Year Change | 72.00% |
| 33 Year Change | -58.65% |
| 5 Year Change | -81.39% |
| Change since IPO | -95.33% |
Recent News & Updates
Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
Sep 21
Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?
May 29Recent updates
Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
Sep 21Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?
May 29We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate
Feb 09We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow
Feb 02We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth
Sep 09Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
May 26Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
Dec 31We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn
Aug 11Shareholder Returns
| CYP | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -8.5% | -3.6% | 1.5% |
| 1Y | 72.0% | 10.0% | 17.2% |
Return vs Industry: CYP exceeded the Australian Biotechs industry which returned 10% over the past year.
Return vs Market: CYP exceeded the Australian Market which returned 17.2% over the past year.
Price Volatility
| CYP volatility | |
|---|---|
| CYP Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: CYP has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: CYP's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Kilian Kelly | www.cynata.com |
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds.
Cynata Therapeutics Limited Fundamentals Summary
| CYP fundamental statistics | |
|---|---|
| Market cap | AU$38.39m |
| Earnings (TTM) | -AU$9.74m |
| Revenue (TTM) | AU$2.32m |
16.8x
P/S Ratio-4.0x
P/E RatioIs CYP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYP income statement (TTM) | |
|---|---|
| Revenue | AU$2.32m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$2.32m |
| Other Expenses | AU$12.06m |
| Earnings | -AU$9.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.054 |
| Gross Margin | 100.00% |
| Net Profit Margin | -420.82% |
| Debt/Equity Ratio | 0% |
How did CYP perform over the long term?
See historical performance and comparison